Zhao Jincun, Zhao Jingxian, Mangalam Ashutosh K, Channappanavar Rudragouda, Fett Craig, Meyerholz David K, Agnihothram Sudhakar, Baric Ralph S, David Chella S, Perlman Stanley
State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA.
Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA.
Immunity. 2016 Jun 21;44(6):1379-91. doi: 10.1016/j.immuni.2016.05.006. Epub 2016 Jun 7.
Two zoonotic coronaviruses (CoVs)-SARS-CoV and MERS-CoV-have crossed species to cause severe human respiratory disease. Here, we showed that induction of airway memory CD4(+) T cells specific for a conserved epitope shared by SARS-CoV and MERS-CoV is a potential strategy for developing pan-coronavirus vaccines. Airway memory CD4(+) T cells differed phenotypically and functionally from lung-derived cells and were crucial for protection against both CoVs in mice. Protection was dependent on interferon-γ and required early induction of robust innate and virus-specific CD8(+) T cell responses. The conserved epitope was also recognized in SARS-CoV- and MERS-CoV-infected human leukocyte antigen DR2 and DR3 transgenic mice, indicating potential relevance in human populations. Additionally, this epitope was cross-protective between human and bat CoVs, the progenitors for many human CoVs. Vaccine strategies that induce airway memory CD4(+) T cells targeting conserved epitopes might have broad applicability in the context of new CoVs and other respiratory virus outbreaks.
两种人畜共患冠状病毒——严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)——已经跨越物种屏障,导致人类严重呼吸道疾病。在此,我们表明,诱导针对SARS-CoV和MERS-CoV共有的保守表位的气道记忆性CD4(+) T细胞,是开发泛冠状病毒疫苗的一种潜在策略。气道记忆性CD4(+) T细胞在表型和功能上与肺源性细胞不同,对于小鼠抵抗这两种冠状病毒都至关重要。保护作用依赖于干扰素-γ,并且需要早期诱导强大的固有免疫和病毒特异性CD8(+) T细胞应答。在感染SARS-CoV和MERS-CoV的人类白细胞抗原DR2和DR3转基因小鼠中也识别出了该保守表位,表明其在人类群体中具有潜在相关性。此外,该表位在人类冠状病毒和蝙蝠冠状病毒(许多人类冠状病毒的祖先)之间具有交叉保护作用。诱导靶向保守表位的气道记忆性CD4(+) T细胞的疫苗策略,可能在新型冠状病毒和其他呼吸道病毒爆发的情况下具有广泛适用性。